𝗧𝗘𝗦𝗔𝗠𝗢𝗥𝗘𝗟𝗜𝗡 — 𝗪𝗛𝗔𝗧 𝗜𝗧 𝗜𝗦, 𝗛𝗢𝗪 𝗜𝗧 𝗪𝗢𝗥𝗞𝗦 & 𝗪𝗛𝗔𝗧 𝗧𝗢 𝗘𝗫𝗣𝗘𝗖𝗧

Tesamorelin is a GHRH analog. GHRH stands for growth hormone-releasing hormone. Basically, instead of giving the body growth hormone from the outside, tesamorelin sends a signal to your pituitary gland telling it to release more of your own growth hormone.

Think of the pituitary as the factory and tesamorelin as someone calling the factory and saying, “Hey, increase production.”

That increased growth hormone then travels through the bloodstream and signals the liver and other tissues, which leads to an increase in IGF-1. So the pathway is basically:

Tesamorelin → pituitary → growth hormone → liver/tissues → increased IGF-1.

And that distinction matters. Tesamorelin isn’t HGH. It’s working upstream and using your body’s own growth-hormone system.

So why has tesamorelin gotten so much attention?

One of the most interesting areas of research is visceral fat. That’s the deeper abdominal fat that surrounds the organs—not just the soft fat you can grab around your waist.

Tesamorelin has actually been studied in humans for its ability to reduce visceral abdominal fat. That’s very different from saying it’s simply a “weight-loss peptide.” You may see changes in body composition without seeing a dramatic change on the scale.

And that’s something people need to understand going into the research.

What should you expect?

Don’t think of tesamorelin like a GLP-1 where appetite can change relatively quickly. The growth-hormone/IGF-1 pathway works differently.

Changes in body composition are generally something researchers look at over months, not days.

The other thing I would pay attention to is IGF-1. If you’re researching compounds that stimulate growth hormone, IGF-1 is one of the most important biomarkers for understanding the downstream response. More isn’t automatically better.

Tesamorelin can also affect glucose metabolism, and reported adverse effects in human studies include things like injection-site reactions, swelling or fluid retention, joint or muscle discomfort, and increased IGF-1.

So the big takeaway is this:

Tesamorelin stimulates the body’s own growth-hormone pathway. It signals the pituitary to increase growth hormone, which can increase IGF-1 downstream. What makes it especially interesting is the human research showing reductions in visceral abdominal fat.

It’s not something where you should expect to wake up a week later completely different. Think body composition, think visceral fat, think GH and IGF-1—and think in terms of months rather than days.

That’s tesamorelin in simple terms.

6:53

1 comment

𝗧𝗘𝗦𝗔𝗠𝗢𝗥𝗘𝗟𝗜𝗡 — 𝗪𝗛𝗔𝗧 𝗜𝗧 𝗜𝗦, 𝗛𝗢𝗪 𝗜𝗧 𝗪𝗢𝗥𝗞𝗦 & 𝗪𝗛𝗔𝗧 𝗧𝗢 𝗘𝗫𝗣𝗘𝗖𝗧